The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis
Abstract
Objective: To assess survival and incidence of organ‐based complications in a large single‐center cohort of unselected systemic sclerosis (SSc) patients, and to explore predictors of survival and clinically significant pulmonary fibrosis (PF) and pulmonary hypertension (PH). Methods: The study cohort consisted of 398 consecutive SSc patients, followed up for up to 15 years. Cox proportional hazards analysis with demographic, clinical, and laboratory characteristics as predictor variables was used to develop prediction models for pulmonary complications and survival. Results: The overall survival estimate at the end of followup was 57% among patients with limited cutaneous SSc (lcSSc) and 50% among patients with diffuse cutaneous SSc (dcSSc) ( P = 0.017). We found that greater age at disease onset, dcSSc, lower diffusing capacity for carbon monoxide (DL co ), lower hemoglobin levels, higher serum creatinine levels, and the presence of PH or cardiac involvement were independent predictors of worse survival. Over the entire followup period, 42% of dcSSc patients and 22% of lcSSc patients developed clinically significant PF ( P < 0.001). The variables that predicted clinically significant PF development were dcSSc, greater age at onset, lower forced vital capacity and DL co , and the presence of anti–topoisomerase I antibody, while the presence of anticentromere antibody was protective. There was no difference in cumulative incidence of PH between the 2 subsets—24% in lcSSc and 18% in dcSSc ( P = 0.558). Incidence rates were 1–2% per year. The PH prediction model demonstrated that greater age at onset, increase in serum creatinine levels, lower DL co , and the presence of anti–RNA polymerase III or anti–U3 RNP antibodies were associated with increased risk of PH, while anti–topoisomerase I antibody positivity reduced the hazard. Conclusion: Our study provides data on long‐term outcome of SSc and the timing and frequency of major organ complications. The predictive models we present could be used as clinical tools for patient risk stratification and could facilitate cohort enrichment for event‐driven studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Changes in causes of death in systemic sclerosis, 1972–2002
Steen, V. D., & Medsger, T. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066068 · Cited by 1,528
Tyndall, A. J., Bannert, B., Vonk, M., Airò, P., Cozzi, F., Carreira, P. E., Bancel, D. F., Allanore, Y., Müller-Ladner, U., Distler, O., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.114264 · Cited by 1,443
Self-citationInterstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,230
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., Müller-Ladner, U., Bocelli-Tyndall, C., & Matucci-Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 929
Self-citationClements, P. J., Lachenbruch, P. A., Siebold, J., White, B., Weiner, S. J., Martin, R. W., Weinstein, A., Weisman, M. H., Mayes, M. D., & Collier, D. H. (1995) · PubMed · Cited by 874
Steen, V., & Medsger, T. A. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10775 · Cited by 494
Elhai, M., Meune, C., Avouac, J., Kahan, A., & Allanore, Y. (2012) · Rheumatology · doi:10.1093/rheumatology/ker269 · Cited by 460
Humbert, M., Yaici, A., de Groote, P., Montani, D., Sitbon, O., Launay, D., Gressin, V., Guillevin, L., Clerson, P., Simonneau, G., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30541 · Cited by 379
SCUSSEL-LONZETTI, L., JOYAL, F., RAYNAULD, J.-P., ROUSSIN, A., RICH, É., GOULET, J.-R., RAYMOND, Y., & SENÉCAL, J.-L. (2002) · Medicine · doi:10.1097/00005792-200203000-00005 · Cited by 361
AVOUAC, J., AIRÒ, P., MEUNE, C., BERETTA, L., DIEUDE, P., CARAMASCHI, P., TIEV, K., CAPPELLI, S., DIOT, E., VACCA, A., et al. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100245 · Cited by 333
Cited by
Denton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,078
Allanore, Y., Simms, R., Distler, O., Trojanowska, M., Pope, J., Denton, C. P., & Varga, J. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.2 · Cited by 876
Self-citationTocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Khanna, D., Lin, C. J. F., Furst, D. E., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., Matucci-Cerinic, M., Distler, O., Shima, Y., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30318-0 · Cited by 662
Self-citationVolkmann, E. R., Andréasson, K., & Smith, V. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01692-0 · Cited by 616
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
Sullivan, K. M., Goldmuntz, E. A., Keyes-Elstein, L., McSweeney, P. A., Pinckney, A., Welch, B., Mayes, M. D., Nash, R. A., Crofford, L. J., Eggleston, B., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1703327 · Cited by 603
Bellan, M., Soddu, D., Balbo, P. E., Baricich, A., Zeppegno, P., Avanzi, G. C., Baldon, G., Bartolomei, G., Battaglia, M., Battistini, S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.36142 · Cited by 474
Hoffmann-Vold, A.-M., Allanore, Y., Alves, M., Brunborg, C., Airó, P., Ananieva, L. P., Czirják, L., Guiducci, S., Hachulla, E., Li, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217455 · Cited by 357
Hoffmann-Vold, A.-M., Maher, T. M., Philpot, E. E., Ashrafzadeh, A., Barake, R., Barsotti, S., Bruni, C., Carducci, P., Carreira, P. E., Castellví, I., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30144-4 · Cited by 310
Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
Cottin, V., & Brown, K. K. (2019) · Respiratory Research · doi:10.1186/s12931-019-0980-7 · Cited by 292
Tenascin-C drives persistence of organ fibrosis
Bhattacharyya, S., Wang, W., Morales-Nebreda, L., Feng, G., Wu, M., Zhou, X., Lafyatis, R., Lee, J., Hinchcliff, M., Feghali-Bostwick, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms11703 · Cited by 292
Jaeger, V. K., Wirz, E. G., Allanore, Y., Rossbach, P., Riemekasten, G., Hachulla, E., Distler, O., Airò, P., Carreira, P. E., Balbir Gurman, A., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163894 · Cited by 268
Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort
Hoffmann-Vold, A.-M., Fretheim, H., Halse, A.-K., Seip, M., Bitter, H., Wallenius, M., Garen, T., Salberg, A., Brunborg, C., Midtvedt, Ø., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0486oc · Cited by 257
Young, A., Vummidi, D., Visovatti, S., Homer, K., Wilhalme, H., White, E. S., Flaherty, K., McLaughlin, V., & Khanna, D. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40862 · Cited by 85
Moreno-Moral, A., Bagnati, M., Koturan, S., Ko, J.-H., Fonseca, C., Harmston, N., Game, L., Martin, J., Ong, V., Abraham, D. J., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212454 · Cited by 78
Self-citation
Metadata
- Authors
- Nihtyanova, S. I., Schreiber, B. E., Ong, V. H., Rosenberg, D., Moinzadeh, P., Coghlan, J. G., Wells, A. U., & Denton, C. P.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2014-05-27
- Volume
- 66
- Issue
- 6
- Pages
- 1625-1635
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W1582069062
- Cited by
- 460
- References
- 33
- FWCI
- 23.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.